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Abstract OBJECTIVES: Premature ovarian failure (POF) is a consequence of gonadotoxic 
chemoradiotherapy given in antyneoplasia treatment. In young women it will cor-
relate with menopausal symptoms which tend to appear due to depleted ovarian 
follicle reserve.
DESIGN: It was a case series study that included women 18–50 years old who 
were treated for malignancy with gonadotoxic chemioradiotherapy. We have 
measured blood hormonal levels of follicle stimulating hormone (FSH), lutein-
izing hormone (LH), estradiol (E2) and progesterone within one month of various 
hormone replacement therapy (HRT).
RESULTS: We have observed different kind of hormonal reaction according to 
FSH, LH, estradiol and progesterone levels due to various hormonal replacement 
therapy. The administration of various HRT regimens presented with a decrease 
in the blood concentration of estradiol E2 and progesterone and a concomitant 
increase of FSH and LH. These findings demonstrate a shift to physiological 
ranges and a simultaneous improvement of symptoms associated with CI-POF. 
CONCLUSIONS: The most appropriate therapy needs to be selected according to 
the patient’s alleviation of symptoms and correction of blood hormone levels.
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INTRODUCTION
Chemotherapy for hematological cancers is associated 
with Premature Ovarian Failure (POF). The gonado-
toxic effect may be temporary or permanent. Women 
who were administered high doses of antineoplastic 
treatment experience so-called Chemotherapy-induced 
Premature Ovarian Failure (CI-POF) (Beard et al. 1984; 
Wang et al. 2010) due to depleted ovarian follicle reserve. 
The estrogen and progesterone depleted patient suffers 
from premature menopause with hot flashes (Heinz 
2010), osteoporosis (Amarante et al. 2011), vaginal dry-
ness, amenorrhea (Tfayli & Arslanian 1998), dyspareu-
nia, infertility (Moline et al. 2005) and psychological 
disturbances (De Vos et al. 2010; Maclaran et al. 2010). 
POF is often treated with hormone replacement ther-
apy (HRT) (Cartwright et al. 2010; Mulder 1999). The 
purpose of this study was to measure hormonal levels 
of patients who underwent chemotherapy for various 
hematological disorders. Various HRT plans were used 
for the correction of hormone levels and symptoms of 
CI-POF (Verschuuren et al. 2006).
MATERIALS AND METHODS
This was a case series study that included women 18–50 
years of age who were treated with gonadotoxic chemo-
therapy at the Hematology Department of the Univer-
sity Hospital in Kraków, Poland between June 2003 and 
December 2009.
33 patients were included in the study. Diagnoses, 
various treatment regimens and duration of treatment 
were evaluated. Inclusion criteria of patients were 
being female, 18–50 years old, treated for malignancy 
with various gonadotoxic chemotherapy regimens 
(Kreuser et al. 1992). For Hodgkin lymphoma (Chap-
man et al. 1979; Haukvik et al. 2006; Verschuuren et al. 
2006) BEACOPP (Grigg 2004) (Bleomycin, Etoposide, 
Adriamycin, Cyclophosphamide, Vincristine, Procar-
bazine and Prednisone) and ABVD (Lee et al. 2008) 
(Adriamycin, Bleomycin, Vinblastine, Dacarbazine) 
was administered (Mackie et al. 1996; Clark et al. 1995). 
For non-Hodgkin lymphoma (Lee et al. 2008) CHOP 
(Kreuser et al. 1992) (Cyclophosphamide, Hydroxy-
daunorubicin, Vincristine and Prednisone) and for 
essential thrombocytosis hydroxyurea were given, 
respectively.  In some cases radiotherapy (Larsen et 
al. 1988; Kreuser et al. 1992) was necessary. Radiation 
therapy doses were between 20–35 Gy. Consistent loss 
of ovarian function may result from single doses of 8 
Gy or fractionated doses of 15 Gy. Patients were also 
required to have completed a minimum duration of one 
year after the treatment without any relapses of their 
primary hematological disease.
Clinical evidence of ovarian failure was conducted. 
Estradiol (E2) and progesterone were evaluated as well 
as follicle stimulating hormone (FSH) and luteiniz-
ing hormone (LH) levels. Blood hormone levels were 
drawn at first patient presentation and at one month of 
hormonal replacement therapy (HRT). 
Various types of HRT were administered according 
to the patient’s main complaint. 
Patients without any contraindications to HRT were 
given orally administered HRT. In cases of contraindica-
tions to oral HRT intake (history of hepatic dysfunction 
or dyspepsia), transdermal and subcutaneous admin-
istration were considered. In women complaining of 
vaginal dryness and concomitant dyspareunia as well 
as frequent urinary tract infections (UTI), intravaginal 
forms of HRT (estradiol or estriol) were the choice of 
treatment.  
Patients have been evaluated according to the fol-
lowing measures (Table 1):
1. Demographic information
2. menopausal symptoms
3. Estriol E2 (estradiol), progesterone, FSH, LH
4. HRT type
5. Time of treatment (1 month)
In 33 patients hormone Levels of FSH, LH, E2 (estra-
diol) and progesterone were measured. The data were 
collected upon first visit and after one month. All serum 
measurements were performed in the same laboratory 
using the same assays. 
The patients presented with various types of POF 
symptoms. The most common hot flashes, vaginal dry-
ness, amenorrhea, dyspareunia and signs of osteopo-
rosis. We have also observed affective symptoms such 
as depression and mood disorders. Due to hormonal 
imbalances patients have experienced infertility.
Gynecological examination and transvaginal ultra-
sound were performed in all patients. The myometrium 
was normal. There were no repository follicular struc-
tures in the ovarian tissue. The endometrium remained 
atrophic.
All 33 patients have elevated FSH and LH levels at the 
beginning of the study. Estradiol levels were between 
Tab. 1. Demographic and clinical information
Number of Patients (n) 33
Mean age, years ± 1 SD 32.96 ± 11.87
Mean age at diagnosis, years ± 1 SD 26.67 ± 9.6
Mean time since end of treatment, months ±1 SD 23.54 ± 8.47
Previous pregnancies 20/33 
women
Chemotherapy type See Materials 
and Methods
Radiotherapy (radiation doses between 20-35 Gy 
in all patients)
6/3 
women
Hematopoietic stem cell transplantation 
(subsequent immunosuppressive therapy with 
prednisone)
31/33
women
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<5.0–110.9 pg/ml (mean level: 21.07 ng/ml). Progester-
one levels were between 0.3–1.87 pg/ml (mean level: 0.8 
ng/ml).
FSH levels were very variable and between 
5.0–187.4 mlU/ml (mean level: 90.65 mlU/ml). LH 
levels were between 2.6–128.2 mlU/ml (mean level: 
60.97 mlU/ml).
Only two patients presented with regular cycles 
despite the above-mentioned results. Mean age at the 
diagnosis of hematological disease was 26.67 years and 
the mean time since the end of radio- and chemothera-
peutic treatment was 23.54 months. 
20 patients delivered more than once. All of those 
pregnancies took place before the presentation of the 
hematological disease.
Various hormonal replacement therapy (HRT) 
regimens were prescribed in all patients. This included 
combinations of oral and transdermal HRT, only trans-
dermal HRT, only oral HRT, subcutaneous HRT and 
other combinations as well as intravaginal administra-
tion of HRT. 
The aim was to decide which drug regimen pro-
vides the fastest correction of hormone concentration 
and best improvement in symptoms characteristic of 
CI-POF.
The following 22 drug regimens were used:
Categories of drug administration: 
I. Transdermal and oral combinations:
1. Climara® 50 mg (transdermal), Provera® 5 mg 
(oral)
2. Climara® 50 mg (transdermal), Provera® 10 mg 
(oral)
3. Climara® 50 mg (transdermal), Duphastone® 
10 mg (oral)
4. Evra® (transdermal), Gynofer® (oral)
5. Femostone 7 Combi® (transdermal)
6. Oesclim® 25 mg (transdermal), Provera® 5 mg 
(oral)
7. Oesclim® 50 mg (transdermal), Provera® 5 mg 
(oral)
8. Oesclim® 50 mg (transdermal), Duphastone® 
10 mg (oral)
9. Femostone® 2/10 mg (oral)
10. Oesclim® 50 mg (transdermal), Lutein 3® (oral)
II. Only transdermal combinations:
1. Oesclim® 25 mg 
2. Systen Sequi® 
3. Systen Conti® 
III. Only oral combinations:
1. Diane® 35 mg 
2. Duphastone® 10 mg 
3. Lutenyl® 5 mg (Nomegestrol), Tri-Minulet® 
4. Provera® 5 mg, Gynofer®
5. Orgametril® (Lynestrenol) 
IV. Subcutaneous combinations:
1. Depo-Provera® (subcutaneous)
V. Intravaginal and other combinations:
1. Ovestin® (intravaginal ovula), Depo-Provera® 
(subcutaneous)
2. Provera® 5 mg (oral), Menofemme® (oral), Oves-
tin® (intravaginal ovula)
3. Vagifem® (intravaginal pill)
Changes in hormone concentrations of estradiol, 
progesterone, FSH and LH were measured with vari-
ous above-mentioned drug regimens. 31 of 33 patients 
reported a subjective improvement in at least one of the 
CI-POF symptoms. All patients reported to be compli-
ant with the treatment regimen. 
Six out of 33 patients have taken the drug regimen 
with 50 mg Oesclim® (Estradiol), Provera® (Medroxy-
progesterone). 2 patients have been administered 
Depo-Provera® (Medroxyprogesterone) alone. 
2 patients have taken 25 mg of Oesclim® and Pro-
vera,® and 2 patients have taken Oesclim® 50mg and 
Duphastone® (Dydrogesterone). All other individual 
patients have taken one of the remaining drug regimens.
Figure 1 depicts the results for the concentration of 
estradiol in the beginning of the study (red column) 
and its concentration after one month (blue column). 
The shaded green area describes the normal serum 
concentration of estradiol of healthy women during 
reproductive age. 
The results show that various drug regimens present 
with variable final results in the concentration of estra-
diol. Elevation of this hormone from “below normal” 
levels to over 100 pg/ml was observed.  
Fig. 1. Effects on estradiol E2.
Mean
Vagifem®
Provera® 5 mg, Menofemme®, Ovestin®
Ovestin® , Depo-Provera®
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Depo-Provera®
IV. Subcutaneous combinations
Orgametril® (Lynestrenol)
Provera® 5 mg, Gynofer®
Lutenyl® 5 mg (Nomegestrol), Tri-Minulet®
Duphastone® 10 mg
Diane® 35 mg
III. Only oral combinations
Systen Conti®
Systen Sequi®
Oesclim® 25 mg
II. Only transdermal combinations
Oesclim® 50 mg, Duphastone® 10 mg
Oesclim® 50 mg, Lutein 3®
Femostan® 2/10 mg
Oesclim® 50 mg, Provera® 5 mg
Oesclim® 25 mg, Provera® 5 mg
Femostone 7 Combi®
Evra®, Gynofer®
Climara® 50 mg, Duphastone® 10 mg
Climara® 50 mg, Provera® 10 mg
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A drug regimen showing a rise of <20% in the mea-
sured estradiol concentration may be designated as 
mildly effective in CI-POF, a drug regimen showing 
a rise of 20–50% as moderately effective and a rise of 
>50% within a month is highly effective in the correc-
tion of estradiol levels.
The following list presents which drug regimen has 
the best measurable efficacy in elevating the serum con-
centration of estradiol within one month of daily drug 
intake:
Mild Efficacy:
Depo-Provera®
Diane® 35
Duphastone® 10 mg
Evra®, Gynofer®
Oesclim® 25 mg, Provera® 5 mg
Ovestin®, Depo-Provera®
Vagifem®
Moderate Efficacy:
Climara® 50 mg, Provera® 5 mg   
Climara® 50 mg, Duphastone® 10 mg
Oesclim® 25 mg
Systen Sequi®
High Efficacy:
Climara® 50 mg, Provera® 5 mg    
Femostone 7 Combi® 
Lutenyl® 5 mg, Tri-Minulet®
Oesclim® 50 mg, Duphastone® 10 mg
Femostone® 2/10 mg
Oesclim® 50 mg, Lutein 3®
Oesclim® 50 mg, Provera® 5 mg
Systen Conti®
The best improvement was observed with the 
administration of the drug Femostone® 2/10 mg. This 
drug combination attained an improvement of approxi-
mately 133.5% above baseline in the serum estradiol 
concentration. The measured starting value rose from 
37 pg/ml to 86.4 pg/ml throughout the study. 
Therefore, the drug regimen of choice for a quick 
relief in CI-POF was oral Femostone® 2/10 mg. 
Similar to estradiol E2, the results show an elevation 
of progesterone (Figure 2).
A drug regimen <20% in the measured hormone 
concentration may be designated as mildly effective, 
a rise of 20–50% as moderately effective and a rise of 
>50% as highly effective. The following list presents 
which drug regimen has the best measurable efficacy 
in elevating the serum concentration of progesterone:
Mild Efficacy:
Diane® 35 mg
Moderate Efficacy:
Lutenyl®, Tri-Minulet®
High Efficacy:
Climara® 50 mg, Provera® 5 mg
Climara® 50 mg, Duphastone® 5 mg
Femostone 7 Combi®
Oesclim® 50 mg
Oesclim® 50 mg, Provera® 5 mg
Orgametril® (Lynestrenol)
System Conti®
Provera® 5 mg, Menofemme®, Ovestin®
Systen Sequi®
The best and fastest improvement in blood proges-
terone concentration was achieved with the oral drug 
Orgametril®. This drug attained an improvement of 
approximately 196% in the blood progesterone concen-
tration within one month of administration. The mea-
sured starting value rose from 0.54 pg/ml to 1.6 pg/ml 
throughout the study. Other highly effective drug regi-
mens were Femostone 7 Combi® with a blood proges-
terone concentration elevation of 178% from 0.57 pg/ml 
to 1.59 pg/ml and Provera® 5 mg, Menofemme®, Oves-
tin® with a blood progesterone concentration of 154% 
from 0.67 pg/ml to 1.7 pg/ml.
Therefore, the drug regimen of choice for relief in the 
treatment of CI-POF with focus on below normal values 
of blood progesterone concentration is Orgametril®. 
The second-line drug regimen is the combination of 
orally given Provera® 5 mg and Menofemme® with intra-
vaginal Ovestin® in ovular form.
Drug regimens used for the alleviation of symptoms 
of CI-POF present with a negative feedback effect on 
the gonadotrophic hormones FSH (Figure 3) and LH 
(Figure 4). Most of the drug regimens used do not 
reduce elevated FSH levels in CI-POF to normal values 
of <20 mlU/ml (Day 3). The only drug combinations Fig. 2. Effects on Progesterone.
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showing a reduction of elevated FSH to normal values, 
which is observed in healthy women during day 3 of 
the menstrual cycle, consist of Climara® 50 mg with 
Provera® 5 mg, Lutenyl® with Tri-Minulet® and Systen 
Sequi®. All other drug regimens, although reducing 
elevated levels of FSH, could not reach normal blood 
FSH levels. 
The most effective drug regimen in reducing 
FSH levels within one month of treatment was oral 
Femostone® 2/10 mg showing a drop of 70.3% from 
107 mlU/ml down to 31.8 mlU/ml.
Similarly to FSH, drug regimens used for the 
improvement of symptoms of CI-POF present with 
a negative feedback effect on LH (Figure 4). Besides 
Vagifem®, all other drug regimens have shown a reduc-
tion of elevated LH blood concentration. No drug regi-
men has been shown to reduce elevated LH levels in 
CI-POF to normal values of <7 mlU/ml (Day 3) within 
one month of treatment. 
The most effective drug regimen in reducing LH 
levels within one month was Orgametril® show-
ing a drop of 73.1% from 65.5 mlU/ml down to 
17.6 mlU/ml. The desired LH blood concentration of 
<7 mlU/ml was not reached within one month.
RESULTS AND DISCUSSION
The decision about which is the best and fastest treat-
ment option in a patient with CI-POF, one has to 
ponder on the patient’s main presenting complaint and 
other comorbidities. While choosing from a multitude 
of hormone replacement plans, the most appropriate 
therapy needs to be selected according to the patient’s 
alleviation of symptoms and correction of blood hor-
mone levels (Mulder 1999).
The best and fastest HRT option for patients with 
below normal values of blood estradiol concentration 
was orally administered Femostone® 2/10 mg.
For those patients with below normal values of 
blood progesterone concentration orally administered 
Orgametril® was most effective.
Patients with a diagnosis of CI-POF also show ele-
vated concentrations of FSH and LH well above physi-
ological levels due to the loss of negative feedback from 
estradiol and progesterone, respectively. 
The administration of various HRT regimens causes 
a decrease in FSH levels to normal physiological levels. 
A decrease to normal physiological levels of FSH could 
only be achieved in patients with the HRT regimens 
consisting of Climara® 50 mg with Provera® 5 mg, Lute-
nyl® with Tri-Minulet® and Systen Sequi®. 
The most effective drug regimen in reducing FSH 
levels within one month of treatment was Femostone® 
2/10 mg.
The administration of various HRT regimens has 
shown that no drug regimen was effective enough in 
reducing elevated LH levels in CI-POF to normal values 
(<7 mlU/ml on Day 3) within one month of treatment. 
Fig. 3. Effects on FSH.
Fig. 4. Effects on LH.
The most effective drug regimen in reducing LH 
levels within one month of treatment was orally admin-
istered Orgametril®. 
More research needs to be conducted whether other 
drug regimens are more effective in causing elevated 
FSH and LH levels to decrease to normal physiological 
values and if long-term elevated FSH and LH levels may 
have a detrimental health effect in CI-POF.
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